DAIICHI SANKYO, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $79B
- Website
- http://daiichisankyo.us
Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease
- Conditions
- Interventions
- First Posted Date
- 2012-04-30
- Last Posted Date
- 2019-01-09
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 110
- Registration Number
- NCT01587651
- Locations
- 🇺🇸
Sinai Center for Thrombosis Research, Baltimore, Maryland, United States
🇺🇸Clinical Pharmacology Unit of Miami, Miami, Florida, United States
🇺🇸Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States
Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- First Posted Date
- 2012-03-29
- Last Posted Date
- 2019-12-27
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 76
- Registration Number
- NCT01565668
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors
- First Posted Date
- 2012-02-03
- Last Posted Date
- 2020-07-16
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 74
- Registration Number
- NCT01525602
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸Univeristy of California, San Francisco, San Francisco, California, United States
🇺🇸Sylvester Comprehensive Cancer Center/UMHC, Miami, Florida, United States
Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects
- Conditions
- Interventions
- First Posted Date
- 2012-01-25
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 28
- Registration Number
- NCT01517399
- Locations
- 🇺🇸
START - South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States
Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)
- Conditions
- Interventions
- First Posted Date
- 2012-01-19
- Last Posted Date
- 2017-10-18
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 29
- Registration Number
- NCT01512199
- Locations
- 🇦🇷
Instituto Damic - Fundacion Rusculleda, Cordoba, Argentina
🇦🇷Unidad de Investigación FP Clinical Pharma en Centro Medico Integral Fitz Roy, Acevedo, Ciudad Autónoma de Buenos Aires, Argentina
🇦🇷Hospital Britanico, Buenos Aires, Argentina
Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SUN13837 Injection in Adult Subjects With Acute Spinal Cord Injury (ASCI)
- Conditions
- Interventions
- First Posted Date
- 2012-01-02
- Last Posted Date
- 2021-01-15
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 65
- Registration Number
- NCT01502631
Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC)
- First Posted Date
- 2011-12-26
- Last Posted Date
- 2020-03-04
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 6
- Registration Number
- NCT01499043
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
- Conditions
- Interventions
- First Posted Date
- 2011-12-21
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 452
- Registration Number
- NCT01496365
Observational Study to Evaluate the Simplified-STroke REhabilitation Assessment of Movement (S-STREAM) Scale in Subjects Who Have Experienced a Nonhemorrhagic Ischemic Stroke
- Conditions
- Interventions
- First Posted Date
- 2011-12-21
- Last Posted Date
- 2021-02-03
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 120
- Registration Number
- NCT01496885
A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)
- First Posted Date
- 2011-11-09
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 13
- Registration Number
- NCT01468467
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸M.D. Anderson Cancer Center, Houston, Texas, United States